Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Other Non Operating Income (2022 - 2025)

Dianthus Therapeutics has reported Other Non Operating Income over the past 4 years, most recently at -$2000.0 for Q3 2025.

  • Quarterly results put Other Non Operating Income at -$2000.0 for Q3 2025, down 101.94% from a year ago — trailing twelve months through Sep 2025 was -$103000.0 (down 1187.5% YoY), and the annual figure for FY2024 was -$64000.0, down 6.67%.
  • Other Non Operating Income for Q3 2025 was -$2000.0 at Dianthus Therapeutics, up from -$30000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for DNTH hit a ceiling of $103000.0 in Q3 2024 and a floor of -$98000.0 in Q1 2025.
  • Median Other Non Operating Income over the past 4 years was -$13500.0 (2023), compared with a mean of -$12833.3.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 786.67% in 2024 and later plummeted 716.67% in 2025.
  • Dianthus Therapeutics' Other Non Operating Income stood at -$2000.0 in 2022, then plummeted by 850.0% to -$19000.0 in 2023, then surged by 242.11% to $27000.0 in 2024, then tumbled by 107.41% to -$2000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$2000.0 (Q3 2025), -$30000.0 (Q2 2025), and -$98000.0 (Q1 2025) per Business Quant data.